Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2019 | Story Charlene Stanley | Photo Supplied
DIABETES read more
The modern clinical research facilities at FARMOVS where the two ground breaking diabetes studies will be conducted.

Diabetes is no longer seen simply as a disease, but as a worldwide epidemic, with alarming increases recorded in both developed and developing countries over the past few years.

About 3,5 million South Africans have diabetes, and many more are unaware that they have it. 

The FARMOVS clinical research facility on the Bloemfontein Campus of the University of the Free State is currently involved in two exciting research studies that could lead to the development of medication for diabetes sufferers burdened by some of its most common complications.

Diabetes in a nutshell

Diabetes is a group of diseases where the sugar (glucose) levels in the blood are too high. 

In diabetes mellitus (DM), the high blood-sugar levels are caused by the body not being able to control the blood-sugar levels properly, because of the body’s inability to produce or use insulin. Insulin is a hormone produced by the pancreas and lowers the blood-sugar levels by helping to move the sugar from the blood into the body cells where the sugar is used as a source of energy.

Type 1 DM is often diagnosed in children or teenagers and occurs when the pancreas does not produce any insulin. Type 2 DM occurs when the pancreas does not make enough insulin, or if the body can no longer use the insulin properly; this is often associated with poor lifestyle choices. Where this type of diabetes used to develop primarily in adults of 40 years and older, it is nowadays not uncommon for children to be diagnosed with it.


It is essential that people who are displaying one or more of the risk factors go for screening. This includes a search Physician at FARMOVS. “If DM is detected early enough, up to 90% of people don’t have to use medication but can address it through changes to their diet and exercise programmes.”

High blood-sugar levels essentially damage the blood vessels, which can lead to long-term implications for a person’s heart, kidneys, eyes, and blood circulation. 
The international studies that FARMOVS forms part of, aim to develop treatments for two of the most common secondary conditions that develop as a result of diabetes. 

Diabetic gastroparesis study

A sufferer’s intestines often don’t function properly due to the damage diabetes causes to the nerves which helps the stomach to empty properly; a condition called gastroparesis. Alleviating this condition, typically marked by abdominal pain, bloating, nausea, vomiting, and early satiety (feeling full after eating only a small amount of food), is the aim of one of the studies.

Diabetic impaired kidney function study

A second research study focuses on developing medication that will have a protective effect on a diabetic’s kidneys.  Although nothing can be done to reverse kidney damage, it is hoped that the treatment will slow down kidney degradation.

Focus on prevention

“Both of these studies are aimed at giving diabetics an increased quality of life, and by no means constitute a cure for their condition,” says Dr Van Jaarsveld.
 “The solution lies in combining the correct and committed use of medication with a decreased calorie intake and an increase in exercise – even if it’s just 30 minutes three times a week.”

Value of educating sufferers

A major benefit for participants in the FARMOVS diabetes research trials, is that they gain valuable insight in their own condition.
Diabetes has been called the ‘silent disease’, since sufferers initially have no symptoms.  For that reason, when the average patient is diagnosed with the disease, he/she already has had it for 10 years.   

For me, diabetes is such a sad disease – especially when you see patients with amputated body parts, knowing that it could have been prevented. It is really up to each individual to take responsibility for their own health,” Dr Van Jaarsveld concludes.

Diabetics who are interested in becoming part of the research studies can register online at www.farmovs.com, or contact FARMOVS at +27 51 410 3111.

News Archive

First doctorate in Thoracic Surgery in Africa awarded
2009-05-12

The University of the Free State (UFS) has become the first university in Africa to award a Ph.D. degree in Thoracic Surgery. The degree was conferred on Prof. Anthony Linegar from the university’s Department of Cardiothoracic Surgery during its recent graduation ceremony.

Thoracic surgery is a challenging subspecialty of cardiothoracic surgery. It began in South Africa in the 1940s and is a broad medico-surgical specialist discipline that involves the diagnosis, operative and peri-operative treatment of acquired and congenital non-cardiac ailments of the chest.

Prof. Linegar became the first academic to conduct a mixed methods analysis of this surgical specialty, which included a systematic review of all the research done in this field in South Africa. The title of his thesis is A Model for the Development of Thoracic Surgery in Central South Africa. The research was based on the hypothesis of a performance gap between the burden of disease in the community and the actual service provision. It makes use of systems theory and project management concepts to develop a model aimed at the development of thoracic surgery.

The research proved that there is a significant under provision of clinical services in thoracic surgery. This was quantified to a factor of 20 times less than should be the case, in diseases such as lung and oesophagus cancer. According to Prof. Linegar, there are multiple reasons for this. Listed amongst these reasons is the fact that thoracic surgery is not part of the undergraduate education in medical training. There tends to be a low level of awareness amongst clinicians as to what the thoracic surgeon offers their patients. The diagnostic and referral patterns in primary and secondary health facilities, where diseases must be picked up and referred early, are not functioning well in this regard. In addition, relatively few cardiothoracic surgeons express an interest in thoracic surgery.

Prof. Linegar’s model is named the ATLAS Mode, which is an acronym for the Advancement of Thoracic Surgery through Analysis and Strategic Planning. It includes the raising of awareness of the role of the specialist thoracic surgeon in the treatment of patients with thoracic diseases as part of the solution to the problem. Furthermore, it aims to develop an accessible and sustainable specialist service that adequately provides for the needs of the community, and that is appropriately represented in health administration circles.

His promoters were Prof. Gert van Zyl, Head of the School of Medicine at the UFS, Prof. Peter Goldstraw, from the Imperial College of London, United Kingdom (UK) and Prof. Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS.

Prof. Linegar has been with the UFS since 2004, is a graduate from Stellenbosch University in 1984 and completed his postgraduate training in Cardiothoracic Surgery at the University of Cape Town. He was granted a Fellowship in Thoracic Surgery at the Royal Brompton Hospital in London, UK and has since held consultant positions at the UFS, Stellenbosch University and in private practice. He has been involved in registrar training since returning from the UK in 1994 and has extensive experience in intensive care medicine. He has published widely, has presented papers at many international conferences, has been invited as a speaker on many occasions and has won awards for best presentation on three occasions.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
12 May 2009
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept